Upadacitinib improves steroid-free clinical and endoscopic endpoints in patients with Crohn's disease: Data from the CELEST study
Panaccione R, Atreya R, Ferrante M, Dubinsky MC, Sands BE, Abreu MT, Cataldi F, Enejosa JV, Zhou Q, Huang B, Lacerda AP, Pangan AL (2018)
Publication Type: Conference contribution
Publication year: 2018
Journal
Book Volume: 12
Pages Range: S412-S413
DOI: 10.1093/ecco-jcc/jjx180.728
Authors with CRIS profile
Raja Atreya
Professur für Translationale Immunforschung bei chronisch entzündlichen Darmerkrankungen (Heisenberg-Professur)
Involved external institutions
AbbVie Deutschland GmbH & Co. KG
Germany (DE)
University of Calgary
Canada (CA)
Icahn School of Medicine at Mount Sinai
United States (USA) (US)
University Hospital Leuven (UZ) / Universitaire ziekenhuizen Leuven
Belgium (BE)
University of Miami
United States (USA) (US)
Germany (DE)
University of Calgary
Canada (CA)
Icahn School of Medicine at Mount Sinai
United States (USA) (US)
University Hospital Leuven (UZ) / Universitaire ziekenhuizen Leuven
Belgium (BE)
University of Miami
United States (USA) (US)
How to cite
APA:
Panaccione, R., Atreya, R., Ferrante, M., Dubinsky, M.C., Sands, B.E., Abreu, M.T.,... Pangan, A.L. (2018). Upadacitinib improves steroid-free clinical and endoscopic endpoints in patients with Crohn's disease: Data from the CELEST study. (pp. S412-S413).
MLA:
Panaccione, R., et al. "Upadacitinib improves steroid-free clinical and endoscopic endpoints in patients with Crohn's disease: Data from the CELEST study." 2018. S412-S413.
BibTeX: Download